<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from Exhibit
99.1 to the Company's Current Report on Form 8-K dated June 12, 1998 for the
period ended December 31, 1997 restated to reflect the combined results of
Incyte Pharmaceuticals, Inc. and Synteni, Inc. and is qualified in its
entirety by reference to such Form 8-K.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
       
                             
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                          55,598
<SECURITIES>                                    57,497
<RECEIVABLES>                                   20,208
<ALLOWANCES>                                       225
<INVENTORY>                                          0
<CURRENT-ASSETS>                               142,914
<PP&E>                                          58,190
<DEPRECIATION>                                  20,120
<TOTAL-ASSETS>                                 199,089
<CURRENT-LIABILITIES>                           52,214
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            26
<OTHER-SE>                                     145,676
<TOTAL-LIABILITY-AND-EQUITY>                   199,089
<SALES>                                              0
<TOTAL-REVENUES>                                89,996
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                72,452
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  7,456
<INCOME-TAX>                                       548
<INCOME-CONTINUING>                              6,908
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     6,908
<EPS-PRIMARY>                                     0.28
<EPS-DILUTED>                                     0.26